Genetic Technologies

Genetic Technologies Ltd. is a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. It operates through EasyDNA and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The GeneType/Corporate segment includes tha GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

Earnings data Q1 2024

Genetic Technologies Ltd. engages in the provision of molecular risk assessment tests for cancer. It operates through the following segments: EasyDNA, AffinityDNA, and GeneType/Corporate. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The AffinityDNA segment deals with AffinityDNA branded test sales and expenses. The GeneType/Corporate segment includes the GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987, and is headquartered in Fitzroy, Australia.

MELBOURNE, Australia, April  01, 2020  (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market.

Genetic Technologies Limited Announces Market Update on Sales, Early Test Results and Launch of Consumer Initiated Testing

MELBOURNE, Australia, March  13, 2020  (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a  leader in the development of genetic risk assessment tests, today announced that after the close of the ASX market on March 13, 2020, it received a determination letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it did not comply with the Listing Rule 5550(b) (the “Equity Rule”) for continued listing on the Nasdaq Capital Market, which requires the Company to have a minimum of $2,500,000 in stockholders’ equity or market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years.

Genetic Technologies Limited Announces Receipt of Delisting Notification Letter from Nasdaq

MELBOURNE, Australia, Jan.  07, 2020  (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) is pleased to advise that its third-generation breast cancer test (GeneType for Breast Cancer) is on track for commercial release in the Unites States (US) in Q1 2020.

20 Medical centers across 8 US states set to offer Breast Cancer Test

MELBOURNE, Australia, Dec.  10, 2019  (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce the full commissioning of its Australian Laboratory for the provisioning of its generation 3 breast cancer test with sales to commence in Q1, 2020.

Genetype for Breast Cancer commissioned with sales to commence First Quarter 2020

MELBOURNE, Australia, Nov.  05, 2019  (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company, announced today an update to shareholders on recent achievements and upcoming milestones.

Genetic Technologies Provides Shareholder Update on Recent Achievements and Upcoming Milestones

Genetic Technologies Limited (NYSE: GENE), a provider of world-leading genetic risk assessment test products today announced that it has signed a 3-year Collaboration Agreement with TGen.

News for Genetic Technologies Stock (GENE)